# CRISPR Therapeutics AG: overview

CRSP · Nasdaq · CIK 1674416 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crsp.md) · [Financials](/companies/crsp/financials.md) · [Filings](/companies/crsp/filings.md) · [Insiders](/companies/crsp/insiders.md)

Latest reported revenue: [$10.2m](/filings/0001193125-26-330672.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-330672).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.6](/filings/0001193125-25-273337.md) | [35.7 d](/filings/0001193125-26-048957.md) | [0.9](/filings/0001193125-26-204188.md) | [0.9](/filings/0001193125-26-330672.md) | [0.9](/filings/0001193125-25-273337.md) | [0.9 d](/filings/0001193125-26-048957.md) | [1.5](/filings/0001193125-26-204188.md) | [10.2](/filings/0001193125-26-330672.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(18294.0%)](/filings/0001193125-25-273337.md) | [(181.0%) d](/filings/0001193125-26-048957.md) | [(17158.8%)](/filings/0001193125-26-204188.md) | [(25709.0%)](/filings/0001193125-26-330672.md) | [(14854.8%)](/filings/0001193125-25-273337.md) | [(17912.5%) d](/filings/0001193125-26-048957.md) | [(8933.3%)](/filings/0001193125-26-204188.md) | [(1151.8%)](/filings/0001193125-26-330672.md) |
| Net margin | % | [(14276.1%)](/filings/0001193125-25-273337.md) | [(104.5%) d](/filings/0001193125-26-048957.md) | [(15722.1%)](/filings/0001193125-26-330672.md) | [(23379.9%)](/filings/0001193125-26-330672.md) | [(11973.1%)](/filings/0001193125-25-273337.md) | [(15117.2%) d](/filings/0001193125-26-048957.md) | [(8431.5%)](/filings/0001193125-26-330672.md) | [(895.3%)](/filings/0001193125-26-330672.md) |
| Diluted EPS | $ per share | [(1.01)](/filings/0001193125-25-273337.md) | not reported | [(1.58)](/filings/0001193125-26-204188.md) | [(2.40)](/filings/0001193125-26-330672.md) | [(1.17)](/filings/0001193125-25-273337.md) | not reported | [(1.28)](/filings/0001193125-26-204188.md) | [(0.94)](/filings/0001193125-26-330672.md) |
| Free cash flow | $m | [(107) d](/filings/0001193125-25-273337.md) | [(50.3) d](/filings/0001193125-26-048957.md) | [(54.2)](/filings/0001193125-26-204188.md) | [(114) d](/filings/0001193125-26-330672.md) | [(84.7) d](/filings/0001193125-25-273337.md) | [(93.1) d](/filings/0001193125-26-048957.md) | [(109)](/filings/0001193125-26-204188.md) | [(84.1) d](/filings/0001193125-26-330672.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [915](/filings/0000950170-24-017571.md) | [1.2](/filings/0000950170-25-017899.md) | [371](/filings/0001193125-26-048957.md) | [37.3](/filings/0001193125-26-048957.md) | [3.5](/filings/0001193125-26-048957.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [40.8%](/filings/0000950170-24-017571.md) | [(56190.4%)](/filings/0000950170-25-017899.md) | [(60.0%)](/filings/0001193125-26-048957.md) | [(1250.4%)](/filings/0001193125-26-048957.md) | [(18933.6%)](/filings/0001193125-26-048957.md) |
| Net margin | % | [41.3%](/filings/0000950170-24-017571.md) | [(54271.7%)](/filings/0000950170-25-017899.md) | [(41.4%)](/filings/0001193125-26-048957.md) | [(981.5%)](/filings/0001193125-26-048957.md) | [(16569.8%)](/filings/0001193125-26-048957.md) |
| Diluted EPS | $ per share | [4.70](/filings/0000950170-24-017571.md) | [(8.36)](/filings/0000950170-25-017899.md) | [(1.94)](/filings/0001193125-26-048957.md) | [(4.34)](/filings/0001193125-26-048957.md) | [(6.47)](/filings/0001193125-26-048957.md) |
| Free cash flow | $m | [457](/filings/0000950170-24-017571.md) | [(533)](/filings/0000950170-25-017899.md) | [(270)](/filings/0001193125-26-048957.md) | [(145)](/filings/0001193125-26-048957.md) | [(346)](/filings/0001193125-26-048957.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crsp/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2018-12-27 | [Vertex Pharmaceuticals (Europe) Ltd](/insiders/1761216.md) | 10% owner | Purchase (P) | 27,461 | $24.9487 | $685.1k | [Form 4](/filings/0001209191-18-064322.md) |
| 2018-12-26 | [Vertex Pharmaceuticals (Europe) Ltd](/insiders/1761216.md) | 10% owner | Purchase (P) | 12,737 | $24.8942 | $317.1k | [Form 4](/filings/0001209191-18-064322.md) |
| 2018-12-24 | [Vertex Pharmaceuticals (Europe) Ltd](/insiders/1761216.md) | 10% owner | Purchase (P) | 53,655 | $24.9687 | $1.3m | [Form 4](/filings/0001209191-18-064099.md) |
| 2018-12-24 | [Vertex Pharmaceuticals (Europe) Ltd](/insiders/1761216.md) | 10% owner | Purchase (P) | 11,742 | $23.1766 | $272.1k | [Form 4](/filings/0001209191-18-064099.md) |
| 2018-12-24 | [Vertex Pharmaceuticals (Europe) Ltd](/insiders/1761216.md) | 10% owner | Purchase (P) | 2,603 | $22.9147 | $59.6k | [Form 4](/filings/0001209191-18-064099.md) |
| 2018-12-21 | [Vertex Pharmaceuticals (Europe) Ltd](/insiders/1761216.md) | 10% owner | Purchase (P) | 22,742 | $22.5784 | $513.5k | [Form 4](/filings/0001209191-18-064099.md) |
| 2016-10-24 | [Glaxosmithkline plc](/insiders/1131399.md) | 10% owner | Purchase (P) | 66,500 | $14.00 | $931.0k | [Form 4](/filings/0000903423-16-001320.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

None of the funds in coverage reports a position in its latest 13F.

## Recent filings

[All 860 filings](/companies/crsp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-11-02 | 16:10 ET | [10-Q](/filings/0001193125-26-443665.md) | Quarterly report, period 2026-09-30 | 0001193125-26-443665 |
| 2026-11-02 | 16:07 ET | [8-K](/filings/0001193125-26-443644.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-443644 |
| 2026-10-19 | 16:11 ET | [8-K](/filings/0001193125-26-425243.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-425243 |
| 2026-08-03 | 16:31 ET | [10-Q](/filings/0001193125-26-330672.md) | Quarterly report, period 2026-06-30 | 0001193125-26-330672 |
| 2026-08-03 | 16:24 ET | [8-K](/filings/0001193125-26-330644.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330644 |
| 2026-06-04 | 16:45 ET | [8-K](/filings/0001193125-26-257593.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257593 |
| 2026-05-04 | 16:48 ET | [10-Q](/filings/0001193125-26-204188.md) | Quarterly report, period 2026-03-31 | 0001193125-26-204188 |
| 2026-05-04 | 16:41 ET | [8-K](/filings/0001193125-26-204147.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-204147 |
| 2026-04-21 | 08:05 ET | [DEF 14A](/filings/0001193125-26-165158.md) | Proxy statement, period 2026-06-04 | 0001193125-26-165158 |
| 2026-03-16 | 16:06 ET | [8-K](/filings/0001193125-26-108333.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-108333 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-048957.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/66ba5922-c5ce-474d-a0c9-e48ffbf04a7a)

## About the filer

- CIK: 1674416
- Tickers: CRSP
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: V8
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Nov 2, 2026, 20:24 ET. No prices; not investment advice.